SeqCureNEO, a T-cell cancer immunotherapy
| Reference number | |
| Coordinator | SeqCure Immunology AB |
| Funding from Vinnova | SEK 3 000 000 |
| Project duration | December 2023 - August 2025 |
| Status | Ongoing |
| Venture | Acceleration of deep tech companies |
| Call | Acceleration of deep tech companies 2023 |
Purpose and goal
The goal of the project is to reach a development stage where venture capital investors are prepared to finance a first clinical study of SeqCureNEO. For this, a study will be conducted based on tissue material (tumor tissue and blood) from cancer patients. The results of the study will be discussed at a scientific advisory meeting with the Swedish Medical Products Agency. The conclusions from this meeting will form the basis for further development towards a first treatment study.
Expected effects and result
SeqCureNEO can enable the treatment of cancer patients who currently have no effective treatment options. The treatment has potential to cure a proportion of patients and to prolong survival for the vast majority. The project work involves a validation of the method in a clinical environment in close collaboration with clinical partners. In consultation with the Swedish Medical Products Agency, we will build on the results in preparation for an upcoming clinical treatment study.
Planned approach and implementation
In collaboration with Uppsala University and Uppsala University Hospital, 5 manufacturing processes starting from tumor tissue and blood from cancer patients will be carried out. Results from these processes will result in verification reports and process documentation which are intended to form the basis for a scientific advisory meeting with the Swedish Medical Products Agency which will be carried out during stage 3 of the project.